Societe Generale’s Myriad Genetics MYGN Stock Holding History

Societe Generale’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	$120K	Buy	+3,908	New	+$136K	﹤0.01%	2315

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Societe Generale's MYGN Position: Q2 2016 in Review

Societe Generale opened a new position in Myriad Genetics (MYGN) in Q2 2016: 3,908 shares worth $120K. The stake represents ﹤0.01% of the portfolio and ranks #2315 among its holdings.

252 funds tracked by Wall St. Rank hold MYGN as of Q2 2016.

Societe Generale held 3,908 shares of Myriad Genetics worth $120K as of Q2 2016.
Myriad Genetics was a new Societe Generale position in Q2 2016.
Myriad Genetics made up ﹤0.01% of Societe Generale's portfolio in Q2 2016, its #2315 holding.
252 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2016.

Based on Societe Generale's 13F filing for Q2 2016, filed 2 Aug 2016.